But in April Medicare stated that it would reimburse dialysis centers for epoetin as long as they reduce dosages when hematocrit levels exceed 39%.

FORBES: Magazine Article

"Amgen essentially purchased the pseudoscience that went into raising these hematocrit guidelines in the medical literature, " bristles Merrill Goozner, a director at the Center for Science in the Public Interest.

FORBES: Magazine Article